Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
04 September 2019 - 9:00PM
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology, today
announced that the Company will present at the 21st Annual H.C.
Wainwright Global Investment Conference on Monday, September 9 at
the Lotte New York Palace Hotel, New York. Spiro Rombotis,
President & Chief Executive Officer, will provide an overview
of the Company and its progress in key programs.
Presentation details are as follows: |
|
|
Date: |
September
9 |
|
|
Time: |
8:20AM – 8:45AM EDT |
|
|
Location: |
Adams, 4th Floor, Lotte New York Palace Hotel |
A live webcast of the presentation will be
available through the Company's website: www.cyclacel.com. The
webcast will be archived for 90 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company developing innovative cancer medicines
based on cell cycle, transcriptional regulation and DNA damage
response biology. The transcriptional regulation program is
evaluating CYC065 in combination with venetoclax in patients with
relapsed or refractory CLL and AML/MDS. The DNA damage response
program is evaluating an oral combination regimen of sapacitabine
and venetoclax in patients with relapsed or refractory AML/MDS. The
anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in
AML/MDS patients. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based
on a pipeline of novel drug candidates. For additional information,
please visit www.cyclacel.com.
Forward-looking StatementsThis
news release contains certain forward-looking statements that
involve risks and uncertainties that could cause actual results to
be materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
Such forward-looking statements include statements regarding, among
other things, the efficacy, safety and intended utilization of
Cyclacel's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ
materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later clinical trials,
trials may have difficulty enrolling, Cyclacel may not obtain
approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of
product candidates. You are urged to consider statements that
include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," or the negative of those words or other
comparable words to be uncertain and forward-looking. For a further
list and description of the risks and uncertainties the Company
faces, please refer to our most recent Annual Report on Form 10-K
and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts |
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Russo Partners LLC, Tony Russo,
(212) 845-4251tony.russo@russopartnersllc.com |
© Copyright 2019 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks
of Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From May 2023 to May 2024